Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134231 | 0.97 | BRAF (0.93) | BRAFRAF1MAPK14 | |
| SCHEMBL4656896 | 0.92 | BRAF (0.85) | BRAF | |
| SCHEMBL4656005 | 0.92 | BRAF (1.00) | BRAF | |
| SCHEMBL4656688 | 0.91 | BRAF (0.84) | BRAFRAF1MAPK14 | |
| SCHEMBL4656510 | 0.91 | BRAF (1.00) | BRAFRAF1MAPK14 | |
| SCHEMBL4655940 | 0.90 | BRAF (0.82) | BRAFRAF1MAPK14 | |
| SCHEMBL4656659 | 0.90 | BRAF (0.81) | BRAFRAF1MAPK14 | |
| SCHEMBL4657119 | 0.89 | BRAF (0.82) | BRAFRAF1MAPK14 | |
| SCHEMBL4655933 | 0.89 | BRAF (0.80) | BRAFRAF1MAPK14 | |
| SCHEMBL4657253 | 0.89 | BRAF (0.82) | BRAFRAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10758526-B2 | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2020-09-01 | — | — | US | disclosed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20170320851-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320850-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | ALBANY MOLECULAR RESEARCH, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9676746-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885RAF1 2308/4885MAPK14 3416/4885 |
| US-10758526-B2 | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | IGLV6-57, IGSF11, TNFRSF9 | BRAF 2156/4885RAF1 3458/4885MAPK14 3320/4885 |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | MKI67, HCCS, NCF1 | BRAF 147/4885RAF1 849/4885MAPK14 4066/4885 |
| US-20170095575-A1 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | IGLV6-57, IGSF11, TNFRSF9 | BRAF 2156/4885RAF1 3458/4885MAPK14 3320/4885 |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BRAF, NRAS, KRAS | BRAF 1/4885RAF1 4/4885MAPK14 142/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885RAF1 2308/4885MAPK14 3416/4885 |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | BRAF 289/4885RAF1 652/4885MAPK14 2409/4885 |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885RAF1 2308/4885MAPK14 3416/4885 |
| US-20170320851-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885RAF1 2308/4885MAPK14 3416/4885 |
| US-20170320850-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | MAL2, ME1, SLC22A11 | BRAF 1869/4885RAF1 1985/4885MAPK14 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.